A- A A+

USA. Opioid-Krise: US-Experten fordern Hepatitis C-Screening aller Erwachsenen

Washington – Die US Preventive Services Task Force (USPSTF) rät allen Erwachsenen im Alter von 18 bis 79 Jahren, sich auf Hepatitis C-Screening testen zu lassen.

Die entsprechende Grad B-Empfehlung wurde im Amerikanischen Ärzteblatt (JAMA 2020; doi: 10.1001/jama.2020.1123) veröffentlicht und mit einem Evidenz-Report begründet (JAMA 2020; doi: 10.1001/jama.2019.20788). Hintergrund ist eine steigende Zahl von Hepatitis C-Erkrankungen infolge der Opioid-Krise und ein Preisrückgang bei den Medikamenten. (aerzteblatt.de, 10.03.2020)

https://www.aerzteblatt.de/nachrichten/110850/Opioid-Krise-US-Experten-fordern-Hepatitis-C-Screening-aller-Erwachsenen

Studie: ASS könnte Hepatitis-Infizierte vor Leberkrebs schützen

Stockholm – Schwedische Erwachsene mit Hepatitis B oder C, die aus anderen Gründen über längere Zeit niedrig dosiert mit Acetylsalicylsäure (ASS) behandelt wurden, erkrankten in einer epidemiologischen Studie im New England Journal of Medicine (2020; 382: 1018-1028) in den Folgejahren seltener an einem hepatozellulären Karzinom. Eine erhöhte Rate von gastrointestinalen Blutungen wurde nicht gefunden. (aerzteblatt.de, 12.03.2020)

https://www.aerzteblatt.de/nachrichten/111032/Studie-ASS-koennte-Hepatitis-Infizierte-vor-Leberkrebs-schuetzen

Drug-Induced Liver Injury EASL Guideline

Idiosyncratic (unpredictable) Drug-Induced Liver Injury is one of the most challenging liver disorders faced by hepatologists. This happens because of the myriad of drugs used in clinical practice. Also due to the available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers.  Therefore, this makes the diagnosis of Drug-Induced Liver Injury an uncertain process. One that requires a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe. It can lead to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed.
This Clinical Practice Guideline summarizes the available evidence on risk factors, diagnosis, management, risk minimization strategies for Drug-Induced Liver Injury. (EASL - The European Association for the Study of the Liver, April 2019) 

https://easl.eu/publication/cpg-drug-induced-liver-injury

A New Generation of Drug Users in St. Petersburg, Russia? HIV, HCV, and Overdose Risks in a Mixed-Methods Pilot Study of Young Hard Drug Users.

Meylakhs P, Friedman SR, Meylakhs A, Mateu-Gelabert P, Ompad DC, Alieva A, Dmitrieva A.

AIDS Behav. 2019 Dec;23(12):3350-3365. doi: 10.1007/s10461-019-02489-6.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788941/

Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.

Schulte B, Wübbolding M, Marra F, Port K, Manns MP, Back D, Cornberg M, Stichtenoth DO, Höner Zu Siederdissen C, Maasoumy B.

Open Forum Infect Dis. 2020 Feb 3;7(2):ofaa040. doi: 10.1093/ofid/ofaa040.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033915/

Hepatitis C Virus Vaccine: Challenges and Prospects.

Duncan JD, Urbanowicz RA, Tarr AW, Ball JK.

Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090. Review.

https://www.mdpi.com/2076-393X/8/1/90

Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection.

Ibrahim MG, Sharafeldin AA, Mousa NI, Mousa TK, El Missiri AM.

Egypt Heart J. 2020 Feb 7;72(1):7. doi: 10.1186/s43044-020-0042-y.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005241/

Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment.

Kim NJ, Pearson M, Vutien P, Su F, Moon AM, Berry K, Green PK, Williams EC, Ioannou GN.

Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996340/

Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program.

Abdel-Razek W, Hassany M, El-Sayed MH, El-Serafy M, Doss W, Esmat G, Waked I.

Clin Liver Dis (Hoboken). 2020 Jan 29;14(6):203-206. doi: 10.1002/cld.868. eCollection 2019 Dec. Review. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988418/

High hepatitis C virus infection among female sex workers in Viet Nam: strong correlation with HIV and injection drug use.

Le LN, O'Connor S, Tran TH, Maher L, Kaldor J, Sabin K, Tran HV, Tran QD, Ho VAT, Nguyen TA.

Western Pac Surveill Response J. 2019 Jul 25;10(3):9-18. doi: 10.5365/wpsar.2019.10.1.002.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024697/

Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.

Murai K, Hikita H, Kai Y, Kondo Y, Fukuoka M, Fukutomi K, Doi A, Yamai T, Nakabori T, Fukuda R, Takahashi T, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.

Sci Rep. 2020 Jan 22;10(1):941. doi: 10.1038/s41598-020-57603-9.

https://www.nature.com/articles/s41598-020-57603-9

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany.

Runge M, Krensel M, Westermann C, Bindl D, Nagels K, Augustin M, Nienhaus A.

Int J Environ Res Public Health. 2020 Jan 9;17(2). pii: E440. doi: 10.3390/ijerph17020440.

https://www.mdpi.com/1660-4601/17/2/440

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.

Nardelli S, Riggio O, Rosati D, Gioia S, Farcomeni A, Ridola L.

World J Gastroenterol. 2019 Dec 28;25(48):6928-6938. doi: 10.3748/wjg.v25.i48.6928.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938730/

A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran.

Behzadifar M, Behzadifar M, Bragazzi NL.

BMC Public Health. 2020 Jan 14;20(1):62. doi: 10.1186/s12889-020-8175-1.

https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-8175-1

The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa.

Mahmud, S., Mumtaz, G. R., Chemaitelly, H., Al Kanaani, Z., Kouyoumjian, S. P., Hermez, J. G., and Abu‐Raddad, L. J. ( 2020) 

Addiction, doi.org/10.1111/add.14944.

https://onlinelibrary.wiley.com/doi/full/10.1111/add.14944

Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey.

Van Baelen L, Plettinckx E, Antoine J, Gremeaux L.

Harm Reduct J. 2020 Feb 21;17(1):11. doi: 10.1186/s12954-020-00358-3.

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-020-00358-3

ACCESS TO HEPATITIS C TREATMENT AND CARE AMONG PEOPLE WHO INJECT DRUGS: FAILING PEOPLE MOST DISPROPORTIONATELY AFFECTED

(HepCoalition.org, Frankreich/USA, ISSUE BRIEF FEBRUARY 2020

https://hepcoalition.org/learn/care/article/access-to-hepatitis-c-treatment-and-care-among-people-who-inject-drugs-failing

Leberzirrhose: Empfehlungen zur sicheren Anwendung von Arzneimitteln

Berlin – Eine Leberzirrhose bei einem Patienten kann bekanntlich den Stoffwechsel und die Dosis-Wirkungsbeziehung von Arzneimitteln verändern und das Risiko von Nebenwirkungen erhöhen. Eine niederländische Arbeitsgruppe hat nun evidenzbasierte Empfehlungen für den Einsatz und die Dosierung zahlreicher praxisrelevanter Arzneimittel bei Leberzirrhose erarbeitet. (aerzteblatt.de, 04.02.2020)

https://www.aerzteblatt.de/nachrichten/109152/Leberzirrhose-Empfehlungen-zur-sicheren-Anwendung-von-Arzneimitteln

Highlights for Dental Care as a Hepatitis C Risk Factor: A Review of Literature.

Averbukh LD, Wu GY.

J Clin Transl Hepatol. 2019 Dec 28;7(4):346-351. doi: 10.14218/JCTH.2019.00023. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943210/

Direct‐acting antivirals interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients.

Ing Lorenzini, K, Girardin, F. 

Liver Int. 2020; 40: 32– 44. doi.org/10.1111/liv.14283

https://onlinelibrary.wiley.com/doi/full/10.1111/liv.14283

Hepatitis B virus particles activate toll‐like receptor 2 signaling initial upon infection of primary human hepatocytes. 

Zhang, Z., Trippler, M., Real, C.I., Werner, M., Luo, X., Schefczyk, S., Kemper, T., Anastasiou, O.E., Ladiges, Y., Treckmann, J., Paul, A., Baba, H.A., Allweiss, L., Dandri, M., Gerken, G., Wedemeyer, H., Schlaak, J.F., Lu, M. and Broering, R. (2020), 

Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31112

https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31112

Hepatitis-B-Viren: Leberzellen nicht wehrlos

Das Hepatitis-B-Virus (HBV) wurde 1970 entdeckt und ist bis heute von wissenschaftlichem Interesse. Nistet es sich im Körper ein, löst es eine Infektion der Leber aus, die in bis zu 10 Prozent der Fälle chronisch verläuft. Offen ist immer noch die Frage, wie es der Erreger schafft, das Immunsystem zu überwinden. Vielleicht könnte diese Entdeckung zur Lösung beitragen: Ein Team der Medizinischen Fakultät der Universität Duisburg-Essen (UDE) hat herausgefunden, wie es dem Immunsystem gelingen kann, das Virus abzuwehren. (Universität Duisburg-Essen,21.01.2020)

https://idw-online.de/de/news730254

High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011–2014: missed opportunities for hepatitis C testing.

Enkelmann, J., Gassowski, M., Nielsen, S. et al. 

Harm Reduct J 17, 7 (2020) doi:10.1186/s12954-019-0338-y

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0338-y

Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).

Marcellin F, Di Beo V, Aumaitre H, Mora M, Wittkop L, Duvivier C, Protopopescu C, Lacombe K, Esterle L, Berenger C, Gilbert C, Bouchaud O, Poizot-Martin I, Sogni P, Salmon-Ceron D, Carrieri P; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2020 Jan 7. pii: S0168-8278(19)30646-4. doi: 10.1016/j.jhep.2019.10.019. 

https://www.journal-of-hepatology.eu/article/S0168-8278(19)30646-4/fulltext

Wechselwirkungen mit HCV-DAA-Medikamenten – Update on hep-druginteractions.org

We have added some new comedications to the interaction checker, at the request of some of our users. You can now look up interactions with alcohol, cannabidiol (CBD), carfentanil, clofazimine, heroin and mesna. (The University of Liverpool’s HEP Drug Interactions Checker, UK, 06.01.2020)

https://hep-druginteractions.org/checker

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.

Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT.

BMC Infect Dis. 2019 Dec 2;19(1):1019. doi: 10.1186/s12879-019-4524-z.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889318/

An Investigation of the Side Effects, Patient Feedback, and Physiological Changes Associated with Direct-Acting Antiviral Therapy for Hepatitis C.

Wu PS, Chang TS, Lu SN, Su HJ, Chang SZ, Hsu CW, Chen MY.

Int J Environ Res Public Health. 2019 Dec 7;16(24). pii: E4981. doi: 10.3390/ijerph16244981.

https://www.mdpi.com/1660-4601/16/24/4981

Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves.

El Kassas M, Tawheed A, Eltabbakh M, Kaseb A.

J Hepatocell Carcinoma. 2019 Nov 19;6:183-191. doi: 10.2147/JHC.S206668. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879003/

Dynamic modeling of hepatitis C transmission among people who inject drugs.

Stocks T, Martin LJ, Kühlmann-Berenzon S, Britton T.

Epidemics. 2019 Dec 11;30:100378. doi: 10.1016/j.epidem.2019.100378.

https://www.sciencedirect.com/science/article/pii/S1755436518301555?via%3Dihub

Overview of hepatitis C infection, molecular biology, and new treatment.

Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S.

J Infect Public Health. 2019 Dec 20. pii: S1876-0341(19)30356-9. doi: 10.1016/j.jiph.2019.11.015.

https://www.sciencedirect.com/science/article/pii/S1876034119303569?via%3Dihub